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Gilles F. H. Diercks, MD, PhDa,b
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IgM: immunoglobulin MINTRODUCTION
Bullous pemphigoid is an autoimmune blistering
disease characterized by pruritus, tense blisters and
erosions of the skin or mucosae, subepidermal
splitting, and linear IgG or complement deposition
along the epidermal basement membrane zone
(BMZ), directed against the hemidesmosomal
proteins BP180 and BP230.1 Deposition of IgA in
conjunction with IgG is regularly found in bullous
pemphigoid, whereas deposition of only IgA along
the epidermal BMZ is known as linear IgA disease.
The presence of only immunoglobulin M (IgM)
deposition in pemphigoid has rarely been described
and the relevance of IgM in the pathomechanism of
autoimmune blistering diseases is still debated.2 In
this case report, we describe a peculiar case involving
a patient with bullous pemphigoid clinically, in which
exclusively tissue bound and circulating IgM subclass
antibodies were present, even after many years of
disease activity and follow-up. This case provides
more insight toward the possible role of IgM in the
pathomechanism of bullous pemphigoid.
CASE REPORT
A healthy 49-year-old woman presented with a
6-year history of spontaneous blisters on the lower
extremities, which later extended to her whole body.
Pruritus was not present. The patient originated from
North Africa, and there were no familymembers with
a similar skin disorder.
Physical examination revealed multiple tense
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gen, University Medical Center Groningen, Center forand neck (Fig 1, A). The lesions healed with hyper-
pigmentation, without scarring or milia. The buccal
mucosa showed purpura and bullae (Fig 1, B).
Two 4-mm biopsies were taken from perilesional
and healthy (nonsun-exposed) skin for direct
immunofluorescence microscopy and a blood
sample was taken for serologic examination. The
biopsies showed a strong linear n-serrated
deposition of IgM along the epidermal BMZ
together with complement C3, without
the presence of IgG or IgA (Fig 1, C ). Indirect
immunofluorescence microscopy on salt-split skin
showed a strong epidermal staining (roof) for
IgM, whereas IgG and IgA results were negative
(Fig 1, D). The immunoblot result for BP180 and
BP230 (IgG) was negative. In accordance with the
clinical presentation, a diagnosis of IgM bullous
pemphigoid was made. In the following years,
multiple biopsies and serologic tests were
performed, repeatedly showing deposition of
complement C3 and IgM subclass antibodies only,
without IgA and IgG. Additional laboratory investi-
gation showed no aberrant findings; more speci-
fically, an infection, immunoglobulin deficiency,
and IgM monoclonal gammopathy were ruled out.
At presentation, the patient had already been
treated with high doses of prednisone, azathioprine,Blistering Diseases, Department of Dermatology and Pathology,
Hanzeplein 1, 9700RB, Groningen, the Netherlands. E-mail: g.f.h.
diercks@umcg.nl.
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Fig 1. Clinical and immunopathologic findings of a patient with IgM bullous pemphigoid. A,
Bullae and vesicles on erythematous skin on the upper body, partly hemorrhagic, with
hyperpigmented maculae. B, Mucosal involvement with vesicles and purpura on the buccal
mucosa. C, Direct immunofluorescence microscopy of perilesional skin showing linear
deposition of IgM in an n-serrated pattern (arrowhead). D, Indirect immunofluorescence
microscopy on salt-split skin showing a strong staining of IgM along the epidermal side
(arrowhead); the artificial subepidermal blister is depicted by an asterisk.
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nolate mofetil, doxycycline, and cyclophosphamide.
Because of insufficient result, infusion of human
intravenous immunoglobulin was started (50 g
intravenously per day during 3 consecutive days
per month). For 1 year she received monthly human
intravenous immunoglobulin infusions, which
resulted in complete remission, but after cessation
of the therapy the blisters returned. After this
period, she was treated with mycophenolate
mofetil (500 mg twice a day) and prednisone
(7.5-15 mg/day) for almost a year, which had to be
stopped because of the adverse effects of
headache, dizziness, and malaise. Consequently,
the human intravenous immunoglobulin infusions
were restarted, combined with mycophenolate
mofetil (500 mg twice a day), and resulted in
complete remission within a short period. After
treatment for 4 years with human intravenous
immunoglobulin infusions, the therapy was changed
to rituximab (1000 mg intravenously twice a month).
While the patient was being treated with rituximab,
new blisters developed. After 5 months, the
human intravenous immunoglobulin infusions(50 g intravenously per month) were restarted, and
she is currently in remission.
DISCUSSION
In this case report, we describe a peculiar case
involving a patient with bullous pemphigoid, with
both complement C3 and tissue bound and
circulating IgM subclass antibodies only. Even
more unusual is that this patient after years of
disease activity and follow-up still demonstrated
(circulating) antibodies exclusively from IgM
subclass, without any evidence of class switching.
The presence of complement C3 supported the
diagnosis of bullous pemphigoid because
complement is thought to be an important factor in
the pathogenesis of bullous pemphigoid by the
attraction and activation of inflammatory cells,
normally initiated by IgG antibodies.1,3,4 Although
the reacting antigen could not be proven, because
ELISA against BP180 NC16a and BP230 is unsuitable
for IgM, we believe this IgM must be directed against
one of the hemidesmosomal components and may
be responsible for the activation of complement in
this patient. The first clue was the n-serrated pattern
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corresponded with binding to autoantigens located
above the sublamina densa zone.1,5 Second, the
epidermal staining (roof) in the indirect immunoflu-
orescence microscopy on salt-split skin also pointed
to BP180 and BP230 as the involved antigens.1,6,7
A literature search revealed several case reports of
patients with IgM epidermolysis bullosa acquisita
(Supplemental Table I; available at http://www.jaad.
org).8-10 In our case, epidermolysis bullosa acquisita
was ruled out by the absence of scarring and the
presence of linear deposition of IgM along the
epidermal side in indirect immunofluorescence
microscopy on salt-split skin, and because the linear
deposition showed an n-serrated pattern. The
presence of IgM-only positivity has also been
reported in a case with ocular pemphigoid, in which
solely the ocular mucosa was involved
(Supplemental Table I).11 However, the presence
of an IgM-mediated entity was debated by Velthuis
et al.2 In their article, 25 patients were described with
linear staining of IgM along the epidermal BMZ, but
because of the heterogeneity of the clinical
presentation, the existence of a linear IgM
dermatosis was eventually denied. One patient in
that cohort was thought to have a form of
IgM-mediated bullous pemphigoid and seemed to
match the profile of our case, with clinically bullous
pemphigoid, linear deposition of IgM and
complement C3 along the BMZ, and the presence
of circulating IgM and complement C3 against BMZ
components. Besides the reported 25 cases by
Velthuis et al,2 other cases with deposition of IgM
antibodies at the BMZ have been reported, particu-
larly in pregnant women (Supplemental Table I).
Why no immunoglobulin class switching has
occurred in our patient with bullous pemphigoid
after years of disease activity is unclear because no
evidence was found for a monoclonal IgM
gammopathy or immunodeficiency. The existence
of a cryoglobulinemia or hyper IgM syndrome was
ruled out as well. A possible explanation for the
persistence of high IgM titers would be that
long-lived plasma cells are responsible for the
production of the IgM antibodies. This theory is
supported by the fact that infusion with rituximabdid not result in remission, whereas use of
human intravenous immunoglobulin did.12,13 The
mechanism of action of human intravenous
immunoglobulin is not fully understood, but its
therapeutic effect seems to result from a combination
of mechanisms, in which B cells are involved.13
In conclusion, although the pathogenic role of
IgM could not be proven, we believe these IgM
antibodies must play an important role in the
pathogenesis of bullous pemphigoid in this patient.REFERENCES
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